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BioinformaticsValidated biomarkers predictive of response/resistance to anthracyclines in breast cancer are currently lacking.
The neoadjuvant Trial of Principle (TOP) study, in which patients with estrogen receptor (ER)–negative tumors
were treated with anthracycline (epirubicin) monotherapy, was speciﬁcally designed to evaluate the predictive
value of topoisomerase II-alpha (TOP2A) and develop a gene expression signature to identify those patients who
do not beneﬁt from anthracyclines. Here we describe in details the contents and quality controls for the gene
expression and clinical data associatedwith the studypublished byDesmedt and colleagues in the Journal of Clin-
ical Oncology in 2011 (Desmedt et al., 2011). We also provide R code to easily access the data and perform the
quality controls and basic analyses relevant to this dataset.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license. Boulevard de Waterloo, 1000
08 58.
u).
uscript.
c. Open access under CC BY-NC-ND liceSpeciﬁcationsnsOrganism/cell line/tissuee. Homo sapiens
Strain(s) Patients' breast tumors
Sequencer or array type Affymetrix GeneChip HG-U133PLUS2
Data format Raw data: CEL ﬁles, normalized data: SOFT,
MINIML, TXT and RData
Experimental factors Pathological complete response; age; tumor size;
histological grade; axillary lymph node status;
HER2, TOP2A status by
FISH, distant metastasis free and overall survivalConsent All patients gave their written informed consent
before study entry.Direct link to deposited data
Deposited data can be found here: http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE16446.
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Study population and clinical data
The neoadjuvant prospective TOP trial (NCT00162812) was
conducted at different European hospitals and coordinated by the
Institut Jules Bordet in Brussels, Belgium. One hundred and forty-nine
patients were included in this trial.
The inclusion criteria were the following: 1/histologically-conﬁrmed
breast cancer (either operable, locally advanced or inﬂammatory),
2/age ≤ 70 yrs, 3/female patient, 4/tumor size ≥ 2 cmat the ultrasound
examination, 5/estrogen receptor (ER)-negative tumors, 6/multifo-
cal and multicentric breast tumors are allowed if all foci are ER-
negative (Table 1.). It is reasonable to limit multifoci tumors to bifo-
cal ones since a ﬁxed and frozen samples should be obtained from
each focus, 7/ﬁxed and frozen samples from the primary tumor, ob-
tained before treatment with epirubicin, must be available for evalu-
ation of biological markers, 8/written informed consent before study
registration, 9/performance status ≤ 1 (ECOG scale), 9/ANC ≥ 1500/
mm3, platelets ≥ 100,000/mm3, Hb ≥ 10 g/dl, total bilirubin and
serum creatinine ≤ 1 N, GOT/GPT ≤ 1.5 N, alkaline
phosphatase ≤ 2.5 N, 10/normal left ventricular ejection fraction
by echocardiography or muga scan, and 11/negative pregnancy test
for all women of childbearing potential.
The exclusion criteria were the following: 1/metastatic breast
cancer, 2/serious medical conditions like: a) congestive heart failure or
unstable angina pectoris, previous history of myocardial infarctionwithin
1 year from study entry, uncontrolled arrhythmias.; b) history ofTable 1
Patient and tumor baseline characteristics for evaluable.
Patients (n = 139)
Characteristic No. of patients %. of patients
Age, years
≤50 86 61.9
N50 53 38.1
Tumor size (at baseline)
T1 20 14.4
T2 99 71.2
T3 5 3.6
T4 15 10.8
Nodal status (at baseline)
N0 69 49.6
N1 64 46.0
N2 3 2.2
N3 3 2.2
Histologic type
Ductal 130 93.5
Lobular 1 0.7
Other 8 5.8
Histologic grade
G1 2 1.4
G2 26 18.7
G3 104 74.8
Gx 7 5.0
HER2 status by FISH
Not ampliﬁed 73 52.5
Ampliﬁed 33 23.7
Missing 33 23.7
Ki67, %
≤25 23 16.5
N25 92 66.2
Missing 24 17.3
pCRa
No 120 86.3
Yes 19 13.7
Abbreviations: HER2, human epidermal growth factor receptor 2; FISH, ﬂuorescent in situ
hybridization; pCR, pathologic complete response.
a The 14 patients who discontinued treatment because of lack of response (n = 11) or
progression (n = 3) were considered to have residual disease for response prediction
analysis.signiﬁcant neurologic or psychiatric disorders, c) active uncontrolled in-
fection, d) active peptic ulcer, unstable diabetes mellitus; 3/concomitant
contra-lateral invasive breast cancer, 4/concurrent treatment with hor-
monal replacement therapy, 5/concurrent treatment with any other
anti-cancer therapy, and 6/previous treatment with anthracyclines for
breast cancer. One patient was not treated according to the protocol due
to ineligibility (concomitant contra-lateral invasive breast cancer).
At completion of chemotherapy, every patient underwent surgery
with axillary node sampling. After surgery, adjuvant docetaxel,
trastuzumab (in case of human epidermal growth factor receptor 2
(HER2)-positive tumors) and loco-regional irradiation were adminis-
tered using standard criteria.
All patients underwent pretreatment core biopsies of the primary
breast tumor before starting neoadjuvant chemotherapy using a 14G
needle. Two biopsies were embedded in OCT (Sakura), frozen in liquid
nitrogen within 5 min and transferred to a −80 °C freezer. Two biop-
sies were ﬁxed in formalin and embedded in parafﬁn. Both ﬁxed and
frozen samples were retrieved by a specialized company and stored at
the Institut Jules Bordet in Brussels (Belgium), where the HER2, topo-
isomerase 2A (TOP2A) and gene expression evaluations were carried
out.
The pathological response assessment and the different TOP2A eval-
uationswere carried out in a blinded fashion: pathological response de-
termination, TOP2A gene, mRNA and protein analyses were conducted
independently.
All pathology reports were centrally reviewed and 17/19 pCRs were
centrally reviewed at the Jules Bordet Institute. Two pCR cases could not
be centrally reviewed since the participating center did not send the
slides to the Jules Bordet Institute.
The clinical data was collected, monitored and validated by the
BrEAST Data Centre, Institut Jules Bordet. The anonymized clinical data
were deposited in the Gene Expression Omnibus database (GEO; [2])
under accession number GSE16446.Gene expression data
One 5-μm tissue section (usually after ten 30-μm sections) of each
biopsy was hematoxylin and eosin stained to monitor the tumor cell
percentage of the tissue. Only specimens with more than 30% of
tumor cells were included for further analysis. Isolation of RNA was
performed using the Trizol method (Invitrogen) according to the
manufacturer's instructions and puriﬁed using RNeasy mini-columns
(Qiagen, Valencia, CA). The quality of the RNA obtained from each
tumor sample was assessed based on the RNA proﬁle generated by the
bioanalyzer (Agilent Inc.). RNA ampliﬁcation, hybridization and image
scanning were done according to standard Affymetrix protocols.
We used the Affymetrix Human Genome U133-2.0 plus GeneChip
according to standard Affymetrix protocols. Microarray and sample
annotation data were deposited in GEO under accession number
GSE16446.Quality control
We used the simpleaffy Bioconductor package [10] to check the
quality of each individual CEL ﬁle. As can be seen in Fig. 1, all the CEL
ﬁles contained a sufﬁciently large percentage of present calls (N40%)
and all the scale factors lie within a 3-fold range, which indicate good
quality according to Affymatrix guidelines [1]. Eighteen CEL ﬁles yielded
larger beta-actin andGAPDH3′/5′ ratios than the threshold published in
theAffymetrix guidelines (Fig. 1),which indicates that RNA degradation
might be an issue for these samples. However there is no consensus
regarding this quality metrics as to what is acceptable or should be
rejected for further analysis, we therefore used all the samples in our
study [3].
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Fig. 2.Histogram of ER mRNA expression in the TOP dataset, which is composed of breast
tumors identiﬁed as ER- by IHC. Two patients had high expression of ER mRNA and were
therefore excluded from further analyses.
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CEL ﬁles were normalized using RMA [6] and probesets were anno-
tated using the chip description ﬁle hgu133plus2cdf and biomaRt pack-
age [4] available from Bioconductor [5]. The sample annotation and the
corresponding documentation are available as supplementary ﬁles of
the series GSE16446 in GEO.
Basic analysis
As we collected patients with breast tumors determined as ER- by
immunohistochemistry (IHC) we double-checked ER negativity with
ER mRNA level. The most variant probeset for ER was considered
(205225_at). We observed that two patients (GSM411367 and
GSM411399) expressed high level of ER mRNA (≥9, Fig. 2). As our
study focused on ER- breast tumors these two patients were excluded
from further analyses.
We then compared HER2 expression (most variant was considered:
210930_s_at) with its ﬂuorescence in situ hybridization (FISH) status.
As expected HER2 was highly expressed in HER2 FISH + tumors
(two-sided Wilcoxon rank sum test p-value = 7E-12, Fig. 3).
We also paid particular attention to TOP2A as it is key in our study of
resistance to anthracycline. TOP2A was represented by three different
Affymetrix probesets: 201291_s_at, 201292_at and 237469_at. The ﬁrst
two probes have been tagged as high quality in the CleanEX database
[9] while the probeset 237469_at exhibited low sequence speciﬁcity.
Supporting this observation, theﬁrst twoprobesetswere highly correlat-
ed (Pearson correlation coefﬁcient N 0.83) while the correlation with
the third one is low (0.56 and 0.52 respectively). Since the probeset
201291_s_at showed the greatest variance [variance of the 3 probesets:Fig. 1. Quality controls for the Affymetrix Raw data generated in [3]. Cel ﬁle name for each
experiment is provided on the left side, followed by the percentage of present and absent
calls (in red) folowing the Affymetrix guidelines. The blue region in the middle of the plot
represents the 3-fold region for scale factor as this region is considered as acceptable
according to Affymetrix guidelines; any scale factor outside this region is drawn in red
as it is considered an indicator of poor quality. Beta-actin and GAPDH 3′–5′ ratios are
also represented on the right side by triangles and circles, respectively; ratio higher than
1.25 are drawn in red as they are considered indicators of poor quality.
HER2 FISH
H
ER
2 
ex
pr
es
sio
n
0 1
10
6
4
8
Fig. 3. Concordance between HER2 mRNA expression and HER2 FISH status. As expected
HER2 mRNA expression was signiﬁcantly higher in HER2 FISH positive tumors versus
HER2 FISH negative tumors (P = 7E-12).
10 B. Haibe-Kains et al. / Genomics Data 1 (2013) 7–10201291_s_at = 1.32, 201292_at = 0.84 and 237469_at = 0.22], we
used it for further analyses.Discussion
We described here a unique dataset of patients with ER- breast
tumor treated with anthracycline. This dataset is composed of clinical
data, including pathological response to anthracycline and genome-
wide gene expression measured using Affymetrix GeneChip platform.
We showed that the gene expression data are of high quality and are
concordant with important clinical parameters. This dataset has been
recently used in studies published in high impact journals [7,8], whichdemonstrate the importance and the beneﬁt of data sharing for biomed-
ical research.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.gdata.2013.09.001.
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